Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin Combined With Gabapentin Versus Solifenacin Monotherapy for Non-neurogenic Overactive Bladder in Women
NCT07429734Phase 3Not yet recruiting
- Sponsor
- Mansoura University
- Start
- Feb 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gabapentin in overactive bladder (OAB) (2 arms), sponsored by Mansoura University. Primary endpoint: Overactive Bladder Symptom Score at 90 days. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
gabapentin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT07429734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429734.